Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This study aims to (1) evaluate efficacy of UDCA in improving liver function and quality of
life; (2) monitor safety, tolerability of UDCA, as well as progression of hepatic sarcoidosis
and liver disease, in patients diagnosed with hepatic sarcoidosis. A minimum of 10 subjects
will be followed for 12 months. For all subjects, initial 6 months will be observational; in
subsequent 6 months, UDCA will be administered. Visits will occur every 3 months and involve
routine blood collection.
Phase:
Phase 2
Details
Lead Sponsor:
Ethan Weinberg
Collaborators:
American Association for the Study of Liver Diseases Exalenz Bioscience LTD.